摘要:
It is intended to provide a novel drug repairing the corneal perception after a corneal surgery and improving the symptoms of dry eye. This drug, which contains an Rho protein inhibitor, is useful for treating depression in corneal perception after a cataract surgery, after an LASIK surgery, after a PRK surgery, or after corneal transplantation, or in association with neuroparalytic keratopathy, corneal ulcer, diabetic keratopathy, etc. and improving dry eye symptoms.
摘要:
The present invention provides a compound represented by the formula (I): (INSERT CHEMICAL FORMULA) (wherein R1 is a lower alkyl substituted by a lower alkoxy or a heterocyclic group, or a heterocyclic group; R2 is a lower alkyl optionally substituted by a phenyl; and R3 is a lower alkyl optionally substituted by a halogen, a lower alkoxy or a phenyl, or a fused polycyclic hydrocarbon group), which is well absorbed orally, exhibits durability of good blood level and has potent calpain inhibitory activity.
摘要翻译:本发明提供由式(I)表示的化合物:(INSERT CHEMICAL FORMULA)(其中R 1是被低级烷氧基或杂环基取代的低级烷基或杂环基; R 2是任选被 苯基;并且R3是任选被卤素,低级烷氧基或苯基或稠合多环烃基团取代的低级烷基),其口服吸收良好,表现出良好的血液水平的持久性并且具有有效的钙蛋白酶抑制活性。
摘要:
A pharmaceutical composition for the prophylaxis and therapy of brain tissue impairment, which contains, as an active ingredient, a compound of formula (I) wherein R represents an alkyl group having 1-4 carbon atoms or an aryl group having 6-10 carbon atoms which is optionally substituted; R and R may be the same or different and each represents hydrogen or an alkyl group having 1-4 carbon atoms or R and R may jointly form a ring having 3-7 carbon atoms; and R represents a lower alkyl group which is optionally substituted by aryl, cycloalkyl, or aromatic heterocyclic residue, or a pharmaceutically acceptable salt thereof.
摘要:
A Maillard reaction inhibitor containing a substance represented by general formula (I), a pharmaceutically acceptable ester thereof, and a pharmaceutically acceptable salt of the substance or the ester, wherein X represents hydroxyl or nitro. It is used for treating or preventing various complications of diabetes, such as coronary artery disease, peripheral circulatory disturbance, cerebrovascular disease, neurosis, nephropathy, arteriosclerosis, arthrosclerosis, cataract and retinitis, and similar diseases caused by aging, such as atherosclerosis, coronary heart disease, cerebrovascular disease, senile cataract, and so forth.
摘要:
Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.
摘要:
A compound of the general formula: (I) wherein each of R1, R2 and R3 represents a lower alkyl group, which compound exhibits a calpain inhibiting activity.
摘要:
An object of the present invention is to provide an agent for promoting proliferation of a meibomian gland epithelial cell and a corneal epithelial cell, as well as provide an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye. There are provided an agent for promoting proliferation of a meibomian gland epithelial cell or a corneal epithelial cell, containing a PPARα or δ agonist as an active ingredient, as well as an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye, containing a PPARα or δ agonist as an active ingredient.
摘要:
The amide compound of the formula (I) [each symbol is as defined in the description] has a promoting action on neuritogenesis of trigeminal nerve cells, and the compound is useful as a corneal neuritogenesis promoter, an agent for recovering corneal sensitivity by promotion of corneal neuritogenesis, and an agent for treating dry eye.